BioSynaptica
Main Vertical
BioTech
CEO/FOUNDER
Name and Surname
Matias Depetris
Linkedin Profile or Bio
Name and Surname
Ricardo Kratje
Linkedin Profile or Bio
Name and Surname
Milagros Bürgi
Linkedin Profile or Bio
Number of people on the Staff
6
Legal Form
Public Limited Company (SA)
Year of Founding
2020
Type of Company
Startup
Development Stage
Validation
Province
Santa Fe
City
Santa Fe
Main Business Model
B2C
Problem
BioSynaptica is a biotechnology startup that seeks to solve one of the great challenges of modern medicine: the lack of effective and safe treatments for chronic and progressive diseases associated with aging, such as neurodegenerative diseases (Alzheimer's, Parkinson's, ALS) and degenerative retinopathies (such as age-related macular degeneration and diabetic retinopathy).
Solutions Offered - Summary
Safe biotherapeutics for neurodegeneration and vision
Solutions Offered - Details
BioSynaptica develops safe, innovative biotherapeutics based on modified human erythropoietin to treat neurodegenerative diseases and chronic retinopathies. The technology removes hematopoietic side effects while preserving neuroprotective and regenerative properties, offering new therapeutic possibilities for millions of people affected by aging-related conditions currently lacking effective trea
Technologies Used
Other
Counterparties of Interest abroad
Accelerator, Financing, Joint Venture, Local Partner, Validation
Industries served
Animal Health, Biotechnology, Health, Pharmaceutical
Investment Round:
Seed
Awards/Recognitions
LATAM $100K 2020 – Entrepreneurship Competition.
Presentation
E-mail
mdepetris@biosynaptica.com
Telephone
543424625309